Skip to content
Sign in
Business opportunities for Neumic Therapeutics Ltd

Why talk

  • Neumic Therapeutics Ltd likely needs funding — BILIX (South Korea, Series A, $13M raised) can offer investor introductions (inferred from public profile).
  • Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), BILIX on Drug for acute kidney injury.
  • BILIX is based in South Korea (Asia): a landing pad on another continent, both ways.

Score by goal: All goals 40 · Market entry 36 · Customers 30 · Investment 47 · Peers 65

Dimension by dimension

Needs ↔ offers

17.5 / 35 pts

BILIX can help Neumic Therapeutics Ltd.

  • Neumic Therapeutics Ltd likely needs funding — BILIX (South Korea, Series A, $13M raised) can offer investor introductions (inferred from public profile).

Market bridge

6.3 / 25 pts

Distant markets.

  • BILIX is based in South Korea (Asia): a landing pad on another continent, both ways.

Customer potential

0.0 / 15 pts

Neither side has a product on the market yet.

Sector synergy

11.3 / 15 pts

Same sector: peers.

  • Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Neumic Therapeutics Ltd works on University therapeutics spin-off (presumed neuroscience), BILIX on Drug for acute kidney injury.

Stage complementarity

4.5 / 10 pts

Weak stage signal.

  • BILIX has raised about $13M — investor introductions are realistic.
  • Stage not comparable (Undetermined / Series A).

How the score works

Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “All goals”: Needs ↔ offers 35, Market bridge 25, Customer potential 15, Sector synergy 15, Stage complementarity 10. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.

Potential blends compatibility (65%) with the mean global score of both startups (35%): 41/100 — high from 50, medium from 36.